Can I Pay For That With My DNA?

The next luxury real estate amenity, after the infinity pool, the private chef, and the helipad, is a longer life.

Lauren Berkowitz · Aug 18, 2026

In Shanghai, a state-owned developer is building an entire neighborhood around a longevity research campus, apartments included. The scientist and CEO whose company anchors the site puts the pitch this way: "In the world of AI, the main success factors will be capital, infrastructure, ideas and the amount of life you have left." The first 114 apartments drew more than 110 buyer groups in a single day. The amenity they bought has not been invented yet.

Shanghai is not alone. Melbourne has an A$1.7 billion development with a reverse aging clinic in the plans, and the first tower sold out. Park City, Utah has one with a $50,000 club fee and a longevity medicine membership for owners. Dubai has a tower coming with a longevity clinic across four amenity floors, and in June Dubai issued Law No. 17, creating a government authority to license research, clinical trials, manufacturing, and patient clinics. On Roatán, off Honduras, a pop-up longevity settlement is converting itself into a permanent biomedical district. The Global Wellness Summit named longevity residences a top trend for 2026. None of these developers are working with each other. They are selling the same thing, an address that is supposed to buy you time.

Alex Zhavoronkov, the CEO and scientist quoted above, whose company Insilico Medicine recently announced a Phase III trial for an AI- discovered drug, asked eight frontier AI models how much today's medicine can extend a human life. The answer was that every worthwhile drug in existence, stacked into one optimized protocol, adds less than two years of life expectancy and roughly eight months of maximum lifespan. Life expectancy is the average, and medicine has moved it. Maximum lifespan is the ceiling, and the ceiling has not moved. The longest verified human life is still 122 years, Jeanne Calment, who died in 1997.

Neither figure says anything about health. Longevity is time plus health, and the health half is what the brochures are actually selling. Healthspan, the years spent well rather than merely alive, is harder to move than the years themselves and much harder to measure. Nobody has published a number for it. The brochures do not use numbers.

Two years and eight months might look small on a spreadsheet or chart. It does not feel small inside a life, where minutes, hours and days represent meaning. An hour is a conversation that would not have happened, a walk, a decision, a day is somebody's birthday. Eight months is about two hundred and forty of those, and every one is priceless.

Priceless sounds great but is not quantifiable, and investors need quantifiable returns. Days delivered, counted, attributed to the building investment that produced them. And no place can do that yet, but the buildings are going up anyway. What these developments are selling really is not longer life, it is a position near where longer life would arrive first, if it arrives. Everyone wants that.

Nobody has explained how any of these places would prove it worked. Prevention is slow and expensive to demonstrate in people who were unlikely to get sick in the first place. Events are rare, timelines run long, and the number of participants needed is usually large. The equity argument about who gets access is the obvious one. The scientific problem is less obvious and it cuts against the developers directly. A building full of healthy, wealthy residents is a difficult place to run a study.

A cohort is a group of people tracked together over time so you can see what happens to them. Bigger ones already exist, UK Biobank has half a million people, recruited between 2006 and 2010 by age and postcode, now sequenced. UK Biobank includes BRCA carriers, and researchers have published cancer risk estimates from them. So size is available.

What UK Biobank does not have is anyone enrolled because of a variant. Carriers turned up later, in the sequencing. UK Biobank consent is based on no feedback of results, so participants were never told, and nothing was done. Nobody was screened, medicated or operated on because of what the data said, which leaves no intervention to measure. Recruitment also started at age 40, after the window where the earliest signals appear. Iceland's deCODE does hold real generations, every Icelander born since 1900 and many of them back to 1700, linked to genotypes, so families followed across time are not unique to hereditary cancer. What deCODE is not built around is a single known cause.

Hereditary cancer cohorts are built the other way. People enroll because of the variant. They are told, they are screened on a schedule for decades, and what happens to them gets recorded, because recording it was the point. Clinical trials win and lose on patient matching.

The science these developments will sell has a history, and it is not the one in the sales brochures. Aging research has a periodic table: twelve hallmarks, the processes of damage and drift that constitute growing old. Every clinic in every one of these developments will sell interventions aimed at some slice of those twelve. Run the hereditary cancer syndromes against the same list and eleven light up. The only miss is the gut microbiome. That tally is mine, a hypothesis, and the hallmarks are broad enough that other disease categories would light up many of the same twelve.

Cells taken from Henrietta Lacks without her knowledge, in 1951, became the first immortal human cell line. Those cells went into the polio vaccine, the HPV vaccine, IVF, gene mapping, and drugs for HIV, leukemia and Parkinson's, and into more than 75,000 studies since. Industries were built on her biology. Henrietta Lacks was in every advance and counted in none of them. That story usually gets told as one about consent and ownership. There is also an accounting version. Value went in, was never recorded, and was never returned.

Admission to everything longevity has built is denominated, so far, in money. The clinics run from a few hundred dollars a year to $150,000. The residences that have published prices start above a million. Many have published nothing at all.

The public marketing talks about circadian lighting and wellness concierges. I searched for anyone publicly stating who these places are for. The Global Wellness Summit's own trend report quotes no developer on the question, and the Summit's analyst offers only that the category is "mostly positioned as ultra-luxury." Newsweek covered the trend in July and got executives on the record about oxygen systems and IV therapy. Nobody seems to be asking.

The question worth asking now, while the plans are open is, what if the application carried a second line next to an applicant's net worth, for what a resident brings in data, appraised in both directions? Backward as credit, because the science these buildings sell was built in part on data from the hereditary cancer community. Forward as value, because the next measured advances will come from that data faster. What if residents in that second column are not study subjects but valuable science partners and neighbors.

The buildings are going up and the financial models are not locked. A cohort that already exists, already consented and already followed, would shorten the time to proof. A community that includes the people whose biology built this science will get answers faster than one that does not.

Sources

NetEase Real Estate and Sina Finance, June 2026 -Up City apartment release) Shanghai municipal government website, republishing Liberation Daily, March 2024 and March 2025 -Up City project)

Daily, January 8, 2025 -Insilico Medicine at the site) Alex Zhavoronkov's public posts (the quotation, and the longevity research campus framing) Developer materials and local press for Elysium Fields -GURNER, Melbourne), Velvære -Park City), Six Senses Residences Dubai Marina -Select Group), and Infinita City -Roatán) Dubai Media Office and Gulf News, June 2026 -Dubai Longevity Authority, Law No. 17 of 2026- Global Wellness Summit, press release January 27, 2026 (longevity residences named a 2026 trend) Insilico Medicine company materials (leadership; rentosertib Phase III, July 2026- Alex Zhavoronkov, "How Much Can You Extend Your Life with Drugs?", Forever.AI, May 8, 2026 Gerontology Research Group and Guinness World Records -Jeanne Calment, 122 years)

UK Biobank, "Our participants" (recruitment design, 2006 to 2010, ages 40 to 69- UK Biobank, "Incidental findings protocol" (participant consent based on no feedback of results) Penetrance estimates of hereditary cancers in a population setting using UK Biobank data, BJC Reports, 2023 Íslendingabók genealogical database and deCODE genetics -Icelandic population genealogy linked to genotypes) CIMBA, Centre for Cancer Genetic Epidemiology, University of Cambridge López-Otín, Blasco, Partridge, Serrano and Kroemer, "Hallmarks of Aging: An Expanding Universe," Cell, January 2023 Shalabi et al., Nature Aging, September 2021 WHO and UN News, October 2021 -HeLa cells) Function Health and Elyx Life, Singapore (clinic pricing) Global Wellness Summit trends explainer by Jane Kitchen, updated April 2026 Newsweek, "Real Estate Pivots to Longevity Residences," July 1, 2026